|
|
|
|
 |
|
|
|
Advanced technology for assessing HIV
Measure resistance to current and future entry inhibitors. PhenoSense Entry™ provides unmatched clinical utility to help you determine whether to start or discontinue Fuzeon® (enfuvirtide). If a failing regimen includes enfuvirtide, you need a complete phenotypic picture of the virus to determine which components to change, as enfuvirtide may still be effective.
Challenges of using entry inhibitors:
- Clinical studies have shown a wide variation in baseline susceptibility
- HIV can become rapidly resistant to enfuvirtide even after brief exposure
When to use PhenoSense Entry™:
- With PhenoSense GT™ in later stages of therapy
- Before changing a regimen that includes Fuzeon
- Before adding Fuzeon if you suspect preexisting resistance
Click on the links below to learn more about PhenoSense Entry™.
Technology
Report Form
|
|
 |
